| Hemochromatosis by drdoc online |
||
|
Hemochromatosis is a disorder of iron metabolism - It is
genetic and as a result there is an accumulation of iron in the tissues
- especially in glandular tissue, pancreas and liver, and skin. The condition is associated with the development of 1.
osteoarthritis of the hips and also interestingly the metacarpal joints
of the hands - especially the index and middle fingers. This produces a crystal arthritis and will mimic a type of gout - with flares over days and subsidence over approx 3 wks per attack. X-rays show calcium deposition in cartilage - This is
seen at the : Untreated - osteoarthritis will develop and the joints will deteriorate.
Treatment of the arthritis is with Nonsteroidal antiinflammatories and
local cortisone injections into the joints - especially the knees. It is important to treat the underlying iron overload and to screen affected family members. Genetic testing Genetic testing for HFE mutations (especially C282Y, H63D, and S65C) is used to confirm hereditary hemochromatosis when iron studies show overload and to screen first‑degree relatives of affected individuals. What the genetic test looks for: Most clinical laboratories test the three common HFE variants — C282Y, H63D, and S65C — which together
account for the majority of adult hereditary hemochromatosis cases. When genetic testing is recommended Clinical guidelines consistently state that genetic testing should be done only when iron overload is proven or strongly suspected: Elevated transferrin saturation (>45%) Testing is also recommended for: C282Y/C282Y Highest risk Most likely to
develop iron overload, though many never develop symptoms Iron studies are still required to
determine whether overload is present Next steps typically include: Family screening for first degree relatives Phlebotomy is the primary and most effective treatment for hereditary hemochromatosis, removing 400–500 mL of blood per session to lower iron stores Each unit removes roughly 200–250 mg of iron. Phase 1: Induction (Iron Depletion) The goal is to rapidly reduce excess iron. Frequency: Weekly or every 2 weeks. Some patients with very high ferritin may tolerate twice‑weekly sessions. Volume:400–500 mL per session. Duration: Several months to >1 year depending on initial ferritin. Ferritin target: <50 μg/L (international guidelines) Some guidelines allow 50-100 μg/L as the endpoint. Monitoring: Hemoglobin before every session; reduce frequency if <12 g/dL, stop if <11 g/dl. Ferritin checked monthly or every 4 - 12 sessions. Phase 2: Maintenance (Lifelong) Once ferritin reaches target, phlebotomy becomes less frequent. Frequency: Every 1-4 months depending on iron reaccumulation. Ferritin target: Maintain 50-100 μg/l. Monitoring: Ferritin every 6 months.; hemoglobin before each session. Safety Parameters Hemoglobin <11 g/dL: stop phlebotomy. Hemoglobin 11-12 g/dL: reduce frequency or volume. Avoid excessive depletion --iron deficiency can occur if monitoring is inadequate. Individual factors influence how often phlebotomy is needed: Baseline ferritin and transferrin saturation. Sex (men reaccumulate faster) Alcohol intake and liver disease. Genetic modifiers affecting iron absorption Alternatives When Phlebotomy Is Not Possible Erythrocytapheresis: fewer sessions per year but higher cost. Iron chelation: reserved for patients who cannot undergo phlebotomy. |
||